scroll to top
0

EBSCO Auth Banner

Let's find your institution. Click here.

Advanced Search Results For "schizophrenia"

1 - 10 of 238,006 results for
 "schizophrenia"
Results per page:

Disorganization domain as a putative predictor of Treatment Resistant Schizophrenia (TRS) diagnosis: A machine learning approach.

Publication Type: Academic Journal

Source(s): Journal of psychiatric research [J Psychiatr Res] 2022 Nov; Vol. 155, pp. 572-578. Date of Electronic Publication: 2022 Sep 29.

Abstract: Background: Treatment Resistant Schizophrenia (TRS) is the persistence of significant symptoms despite adequate antipsychotic treatment. Although consensus guidelines are available, this condition remains often unrecognized and an average delay of 4-9 ...

View details

The impacts of the COVID-19 pandemic on treatment-resistant schizophrenia patients having followed virtual reality therapy or cognitive behavioural therapy: a content analysis.

Publication Type: Academic Journal

Source(s): Annals of medicine [Ann Med] 2022 Dec; Vol. 54 (1), pp. 2477-2485.

Abstract: Purpose: The COVID-19 pandemic led to exacerbation of mental health symptoms and deterioration in psychological well-being in individuals suffering from schizophrenia. The primary objective of this study is to evaluate the impacts of the COVID-19 pande...

View details

Gamma-aminobutyric acid (GABA) levels in the midcingulate cortex and clozapine response in patients with treatment-resistant schizophrenia: A proton magnetic resonance spectroscopy ( 1 H-MRS) study.

Publication Type: Academic Journal

Source(s): Psychiatry and clinical neurosciences [Psychiatry Clin Neurosci] 2022 Nov; Vol. 76 (11), pp. 587-594. Date of Electronic Publication: 2022 Sep 16.

Abstract: Background: Gamma-Aminobutyric Acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system. GABAergic dysfunction has been implicated in the pathophysiology of schizophrenia. Clozapine, the only approved drug for treatment-resi...

View details

Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial.

Publication Type: Academic Journal

Source(s): Military Medical Research [Mil Med Res] 2022 Oct 18; Vol. 9 (1), pp. 59. Date of Electronic Publication: 2022 Oct 18.

Authors:

Abstract: Background: Although clozapine is an effective option for treatment-resistant schizophrenia (TRS), there are still 1/3 to 1/2 of TRS patients who do not respond to clozapine. The main purpose of this randomized, double-blind, placebo-controlled trial w...

View details

Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension.

Publication Type: Academic Journal

Source(s): Schizophrenia research [Schizophr Res] 2022 Oct; Vol. 248, pp. 271-278. Date of Electronic Publication: 2022 Sep 14.

Abstract: Introduction: Treatment resistance constitutes the highest burden of disease within schizophrenia. We hypothesized that the synergistic activity of Lu AF35700 at dopamine D1 and D2 receptors might provide superior antipsychotic effects versus first-lin...

View details

Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia.

Publication Type: Academic Journal

Source(s): Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2022 Dec; Vol. 23 (18), pp. 2035-2052. Date of Electronic Publication: 2022 Nov 17.

Abstract: Introduction: Treatment resistant schizophrenia (TRS), the lack of response to at least two antipsychotics administered at adequate dose and duration, epitomizes in psychiatry one of the most difficult-to-treat pathologies, epidemiologically relevant (...

View details

Effect of add-on alpha lipoic acid on psychopathology in patients with treatment-resistant schizophrenia: a pilot randomized double-blind placebo-controlled trial.

Publication Type: Academic Journal

Source(s): Psychopharmacology [Psychopharmacology (Berl)] 2022 Nov; Vol. 239 (11), pp. 3525-3535. Date of Electronic Publication: 2022 Sep 07.

Abstract: Rationale: Alpha lipoic acid is known to reverse NMDA receptor hypofunction in addition to dopamine receptor blockade activity. It also enhances neurotrophic factors and has antioxidant potential. These properties combined together may be beneficial fo...

View details

Elevated salivary kynurenic acid levels related to enlarged choroid plexus and severity of clinical phenotypes in treatment-resistant schizophrenia.

Publication Type: Academic Journal

Source(s): Brain, behavior, and immunity [Brain Behav Immun] 2022 Nov; Vol. 106, pp. 32-39. Date of Electronic Publication: 2022 Aug 05.

Abstract: Patients with treatment-resistant schizophrenia (TRS) suffer severe, long-term psychotic symptoms and chronic stress. Salivary kynurenic acid (KYNA) and choroid plexus were evidenced to relate to psychological stress. We hypothesized that TRS patients ...

View details

Combination of strategies to initiate clozapine for refractory schizophrenia in a patient with low neutrophil levels.

Publication Type: Academic Journal

Source(s): BMJ case reports [BMJ Case Rep] 2022 Oct 13; Vol. 15 (10). Date of Electronic Publication: 2022 Oct 13.

Abstract: Clozapine is the only drug with confirmed efficacy for refractory schizophrenia; however, its use is restricted due to the risk of potentially life-threatening side effects, such as agranulocytosis. Although this restriction ensures safety against haem...

View details

Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives.

Publication Type: Academic Journal

Source(s): The Australian and New Zealand journal of psychiatry [Aust N Z J Psychiatry] 2022 Oct; Vol. 56 (10), pp. 1295-1305. Date of Electronic Publication: 2021 Nov 17.

Abstract: Objective: Schizophrenia, a complex psychiatric disorder, is often associated with cognitive, neurological and neuroimaging abnormalities. The processes underlying these abnormalities, and whether a subset of people with schizophrenia have a neuroprogr...

View details
sponsored